Lantern Pharma Inc. (LTRN) Shareholder/Analyst Call Transcript

Panna Sharma
President, CEO & Director

Well, first of all, I want to thank everyone for joining us at 8:30 Eastern to see what I think is going to be probably the first real public unveiling of this next-generation withZeta AI platform. Many of you have had some of the fortune to actually see it in the past in demos. Some of you are actually users, which is even better. But we’ve now come up with the next generation. And let me walk you through some of the features.

Just as a reminder, withZeta.ai started as an initiative at Lantern Pharma for us to think about rare cancers. And we’ve been particularly, I would say, both gifted and focused on trying to take our therapies and focus them on challenging or rare cancers, partly as part of a development strategy, but partly also their white space. There are a lot of cancers that basically have no standard of care or a highly unmet need — have high unmet needs. Zeta is actually one of the rare stars. It’s a type of star, Zeta star, and they’re very rare. And so as we kind of thought about this project, we codenamed it withZeta, initially Zeta and then withZeta because as the power of the platform increased, it became more than just a big data platform. It became more than just a RADR platform. It became more than just a platform for going out and gathering information and putting it into nice tables. It does all that.

But it actually started having the ability to reason. We use natural language processing and we tied all our tools together. And it actually